Creatinine versus cystatin C to estimate glomerular filtration rate in adults with congenital heart disease: Results of the Boston Adult Congenital Heart Disease Biobank - 14/07/19
, Matthew Carazo, MD a, b, Michael N. Singh, MD a, b, Konstantinos Dimopoulos, MD, MSc, PhD c, David A. Cardona-Estrada, MD d, Ahmed Elantably, MD d, Sushrut S. Waikar, MD, MPH b, Finnian R. Mc Causland, MBBCh, MMSc b, Gruschen Veldtman, MD e, Jasmine Grewal, MD f, Catherine Gray, BS a, Brittani N. Loukas, PA-C a, Saurabh Rajpal, MBBS, MD gAbstract |
Background |
Glomerular filtration rate is a key physiologic variable with a central role in clinical decision making and a strong association with prognosis in diverse populations. Reduced estimated glomerular filtration rate (eGFR) is common among adults with congenital heart disease (ACHD).
Methods |
We conducted a prospective cohort study of outpatient ACHD ≥18 years old seen in 2012-2017. Creatinine and cystatin C were measured; eGFR was calculated using either the creatinine or cystatin C Chronic Kidney Disease–Epidemiology Collaboration equation (CKD-EPICr and CKD-EPICysC, respectively). Survival analysis was performed to define the relationship between eGFR and both all-cause mortality and a composite outcome of death or nonelective cardiovascular hospitalization.
Results |
Our cohort included 911 ACHD (39 ± 14 years old, 49% female). Mean CKD-EPICr and CKD-EPICysC were similar (101 ± 20 vs 100 ± 23 mL/min/1.73 m2), but CKD-EPICr estimates were higher for patients with a Fontan circulation (n = 131, +10 ± 19 mL/min/1.73 m2). After mean follow-up of 659 days, 128 patients (14.1%) experienced the composite outcome and 31 (3.4%) died. CKD-EPICysC more strongly predicted all-cause mortality (eGFR <60 vs >90 mL/min/1.73 m2: CKD-EPICysC unadjusted HR = 20.2 [95% CI 7.6-53.1], C-statistic = 0.797; CKD-EPICr unadjusted HR = 4.6 [1.7-12.7], C-statistic = 0.620). CKD-EPICysC independently predicted the composite outcome, whereas CKD-EPICr did not (CKD-EPICysC adjusted HR = 3.0 [1.7-5.3]; CKD-EPICr adjusted HR = 1.5 [0.8-3.1]).
Patients reclassified to a lower eGFR category by CKD-EPICysC, compared with CKD-EPICr, were at increased risk for the composite outcome (HR = 2.9 [2.0-4.3], P < .0001); those reclassified to a higher eGFR class were at lower risk (HR = 0.5 [0.3-0.9], P = .03).
Conclusions |
Cystatin C–based eGFR more strongly predicts clinical events than creatinine-based eGFR in ACHD. Creatinine-based methods appear particularly questionable in the Fontan circulation.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| Funding sources: This work was conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic health care centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the National Institutes of Health. This work was also supported by an investigator-initiated study research grant from Roche Diagnostics (Indianapolis, IN). A. R. O. and M. S. are supported by the Dunlevie Family Fund. |
Vol 214
P. 142-155 - Agosto 2019 Ritorno al numero
Articolo precedente
- Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry
- Michael G. Nanna, Ann Marie Navar, Tracy Y. Wang, Shuang Li, Salim S. Virani, Zhuokai Li, Jennifer G. Robinson, Veronique L. Roger, Peter W.F. Wilson, Anne C. Goldberg, Andrew Koren, Michael J. Louie, Eric D. Peterson
- Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis
- Amgad Mentias, Ghanshyam Shantha, Oluwaseun Adeola, Geoffrey D Barnes, Bharat Narasimhan, Konstantinos C. Siontis, Deborah A. Levine, Rajan Sah, Michael C. Giudici, Mary Vaughan Sarrazin
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?